Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu disease, is a hereditary disorder characterized by the development of multiple telangiectasias that lead to recurrent hemorrhages. These microangiopathies can be localized in various areas of the body, including the skin and mucous membranes, and their occurrence is associated with abnormal vascular structures. HHT is caused by genetic mutations that lead to abnormal vascular development and can manifest at any age, sometimes being detected in children. The disease has a significant impact on the quality of life of patients, causing physical and emotional suffering.
History of the disease and interesting historical facts
Hereditary hemorrhagic telangiectasia was first described in 1864 by Norwegian physician Edward Osler. In his works, he described in detail the phenomenon of repeated nosebleeds and conditions accompanied by the appearance of telangiectasias on the skin. In 1907, scientist K. Rendu identified this pathology as a separate nosological unit, and later studies conducted by A. Weber confirmed its hereditary nature. During the 20th century, many cases and descriptions were added to the medical literature, which led to an improved understanding of the pathogenesis and clinical manifestations of this disease. One of the interesting facts is that NHTE can manifest itself not only directly in the family where such cases exist, but also in patients without an obvious hereditary predisposition.
Epidemiology
The prevalence of hereditary hemorrhagic telangiectasia varies by geographic region, but averages approximately 1 in 5,000–8,000 people. Studies show that the disease is equally common among men and women, but women may develop symptoms later in life due to hormonal changes. According to various data, approximately 50% patients experience episodes of nosebleeds in childhood, and more than 90% have clinical manifestations of the disease by the age of 30. This creates a need for early diagnosis and subsequent monitoring of such patients to prevent serious complications.
Genetic predisposition to this disease
Hereditary hemorrhagic telangiectasia is an autosomal dominant disorder, meaning that one copy of a mutated gene is enough to cause clinical symptoms. The most well-known mutations are in the ENG (endoglycin), ALK1 (activin PC), and SMAD4 genes. The ENG and ALK1 genes are responsible for the normal development of vascular structures, and their mutations lead to the formation of abnormally dilated vessels. Studies show that about 85–90% cases of NHTE are associated with mutations in these genes, and about 10% isolated cases may be associated with mutations in the SMAD4 gene. Genetic testing can help in establishing an accurate diagnosis in patients and their relatives.
Risk factors for the development of this disease
Major risk factors for hereditary hemorrhagic telangiectasia include:
- Family history of the disease: Patients who have relatives with NGTE have a higher risk of developing the disease.
- Age: Disease manifestations may vary with age, with early symptoms appearing in childhood.
- Genetic mutations: The presence of mutations in the ENG or ALK1 genes significantly increases the risk of developing telangiectasia.
Research suggests that physical factors such as trauma or high vascular loads may exacerbate disease manifestations, and chemical factors, including possible exposure to carcinogens, may play an indirect role.
Diagnosis of this disease
Diagnosis of hereditary hemorrhagic telangiectasia is based on clinical symptoms, genetic testing, and radiological studies. The main symptoms that indicate NHTE include:
- Multiple telangiectasias on the skin and mucous membranes.
- Nosebleeds, which can be frequent and severe.
- Hemorrhages in other organs, including the stomach and intestines.
Laboratory tests may include tests to detect anemia associated with prolonged bleeding. Radiological tests such as ultrasound, angiography, or magnetic resonance imaging may be used to evaluate the internal state of the vessels and identify potential abnormalities. The differential diagnosis includes a number of vascular diseases and coagulopathies such as Bruton syndrome, cipher telangiectasia, and others.
Treatment
Treatment of hereditary hemorrhagic telangiectasia can be quite complex and varied. The main areas include:
- General treatment aimed at reducing the frequency and severity of bleeding episodes. This may include patient education on how to avoid injury.
- Pharmacological treatment, including the use of blood transfusions, drugs that increase clotting and reduce symptoms.
- Surgical treatment, such as laser therapy or sclerotherapy, to remove telangiectasias or correct vascular abnormalities.
- Other treatments, such as the use of anti-inflammatory drugs to reduce inflammatory reactions in the joint and mucous membranes.
Surgical methods are especially important in patients with severe manifestations and frequent bleeding episodes, which requires an individual approach.
List of medications used to treat this disease
The main groups of drugs used to treat NGTE include:
- Aminocaproic acid – to reduce the frequency of nosebleeds.
- Desmopressin – may be used to increase levels of blood clotting factors.
- Iron-containing preparations – to combat anemia resulting from chronic bleeding.
- Drugs that reduce inflammation and have a general strengthening effect on the body.
It should be noted that the choice of therapy is always individual and based on the clinical picture of the disease.
Disease monitoring
Monitoring a patient with hereditary hemorrhagic telangiectasia involves regular visits to the doctor and observation of the dynamics of the disease. Control stages include:
- Regular examination for the presence of new telangiectasias and assessment of their severity.
- Blood tests to monitor hemoglobin levels and the presence of anemia.
- Periodic radiological examinations to assess the condition of the vessels and possible changes.
The prognosis without proper treatment can be serious, including the risk of severe hemorrhage, anemia, and decreased quality of life. However, with adequate treatment and monitoring, many patients can lead active lives.
Age-related features of the disease
Hereditary hemorrhagic telangiectasia can present at any age. Children are more likely to have nosebleeds and telangiectasias, while adults may experience prolonged episodes of hemorrhage. In older patients, symptoms may be exacerbated by underlying medical conditions and the general condition of the vascular system. It is important to tailor testing and treatment to the age group, as approaches may differ.
Questions and Answers
- What are the main symptoms of hereditary hemorrhagic telangiectasia? The main symptoms include multiple telangiectasias on the skin and mucous membranes, frequent nasal and other hemorrhages, and anemia.
- Can hereditary hemorrhagic telangiectasia be cured? There is currently no cure for the disease, but available treatments can help control symptoms and quality of life.
- How is NGTE diagnosed? Diagnosis includes clinical symptoms, genetic testing, and radiological examinations.
- What is the risk of children inheriting the disease? With one affected parent, the risk of transmission is 50% per offspring.
- What drug therapy is recommended to reduce nosebleeds? Aminocaproic acid and desmopressin are often used to increase blood clotting.
Advice from Dr. Oleg Korzhikov
Paying attention to your health and regularly monitoring your condition is critical for patients with hereditary hemorrhagic telangiectasia. I recommend the following:
- Be sure to keep a disease diary, tracking the frequency and duration of bleeding episodes.
- Seek medical attention immediately if new symptoms or changes in the underlying condition occur.
- Discuss genetic testing with your doctors, especially if you have a family history of NGTE.
- Learn techniques to help you manage your symptoms, such as special blood clotting techniques.
This approach will improve the quality of life and minimize the risks associated with this disease.
